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The Centers for Disease Control and 
Prevention (CDC) recently revised the refer-
ence value for childhood lead exposure down-
ward from 10 to 5 μg/dL (Betts 2012). This 
has occurred in response to evidence show-
ing consistent associations between blood lead 
levels (BLLs) < 10 μg/dL and neurocognitive 
(Bellinger et al. 1992; Lanphear et al. 2005), 
cardiovascular (Gump et al. 2005; Menke 
et al. 2006), and immunologic (Karmaus et al. 
2005) outcomes, as well as pubertal (Kafourou 
et al. 1997; Naicker et al. 2010; Selevan et al. 
2003; Shukla et al. 1991; Williams et al. 2010) 
and growth delay (Ballew et al. 1999; Little 
et al. 2009; Schwartz et al. 1986).
In cross-sectional studies conducted 
in prepubertal children, mean decreases of 
1–1.5 cm in height have been estimated for 
each 10-μg/dL increase in BLL (Ballew et al. 
1999; Little et al. 2009; Schwartz et al. 1986). 
BLL has also been negatively associated with 
height in two pubertal cohorts (Burns et al. 
2012; Selevan et al. 2003). In our prospec-
tive cohort of Russian boys followed annu-
ally from 8 to 13 years of age, boys with BLL 
≥ 5 μg/dL had significantly lower mean height 
z-score (–0.44) than boys with BLL < 5 μg/dL 
(Burns et al. 2012).
A mechanistic explanation for the associa-
tion between lead exposure and growth delay 
in childhood has not been firmly established. 
Studies to this end have been conducted 
almost exclusively in animal models with high 
lead exposures, and results have suggested 
multiple possible mechanisms, perhaps oper-
ating simultaneously, including lead-induced 
reduction in food consumption (Hammond 
et al. 1989, 1990) and direct growth plate 
effects (Hass et al. 1967; Hicks et al. 1996). 
Several rodent studies have also implicated 
lead- mediated suppression of growth hor-
mone (GH) release from the pituitary 
(Camoratto et al. 1993; Lau et al. 1991; Ronis 
et al. 1998a), and consistent with this finding, 
high lead exposure has been associated with 
decreased serum insulin-like growth factor 1 
(IGF-1) concentration in rodents (Ronis et al. 
1998a) and prepubertal children (Huseman 
et al. 1992).
The physiologic mechanisms that mediate 
health outcomes such as growth delay fol-
lowing low lead exposure may be different 
from those operating at higher exposures. 
Mechanistic differences in low- versus high-
dose effects have been demonstrated for 
several environmental chemicals, including 
bisphenol A, atrazine, dioxin, and perchlorate 
(Vandenberg et al. 2012). Because exposures 
to lead and other heavy metals are increasingly 
regulated, a better understanding of the physi-
ologic effects of low-level exposures is needed. 
With regard to growth delay, the relationship 
between low-level lead exposure and serum 
IGF-1 concentration has not been examined.
The present analysis was conducted to 
evaluate the association between childhood 
BLL and longitudinally measured serum 
IGF-1 concentrations and to assess whether 
there is a dose–response relationship between 
BLL and IGF-1 in a large cohort of peri-
pubertal boys with low-level lead exposure.
Methods
Study population. From 2003–2005, we 
recruited 8- to 9-year-old boys in Chapaevsk, 
Russia, to participate in the Russian Children’s 
Study, as previously described (Burns et al. 
2012). Enrollment exclusion criteria included 
being institutionalized or having severe cere-
bral palsy. A total of 499 boys were thus iden-
tified, and they have been followed annually 
since recruitment. For the present analysis, 
10 boys with severe chronic illnesses that could 
affect growth were excluded. Of the remain-
ing 489, two pubertal boys were also excluded 
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Background: Childhood lead exposure has been associated with growth delay. However, the 
association between blood lead levels (BLLs) and insulin-like growth factor 1 (IGF-1) has not been 
characterized in a large cohort with low-level lead exposure.
Methods: We recruited 394 boys 8–9 years of age from an industrial Russian town in 2003–2005 
and followed them annually thereafter. We used linear regression models to estimate the association 
of baseline BLLs with serum IGF-1 concentration at two follow-up visits (ages 10–11 and 12–13 
years), adjusting for demographic and socioeconomic covariates.
results: At study entry, median BLL was 3 μg/dL (range, < 0.5–31 μg/dL), most boys (86%) were 
prepubertal, and mean ± SD height and BMI z-scores were 0.14 ± 1.0 and –0.2 ± 1.3, respectively. 
After adjustment for covariates, the mean follow-up IGF-1 concentration was 29.2 ng/mL lower 
(95% CI: –43.8, –14.5) for boys with high versus low BLL (≥ 5 μg/dL or < 5 μg/dL); this differ-
ence persisted after further adjustment for pubertal status. The association of BLL with IGF-1 was 
stronger for mid-pubertal than prepubertal boys (p = 0.04). Relative to boys with BLLs < 2 μg/dL, 
adjusted mean IGF-1 concentrations decreased by 12.8 ng/mL (95% CI: –29.9, 4.4) for boys with 
BLLs of 3–4 μg/dL; 34.5 ng/mL (95% CI: –53.1, –16.0) for BLLs 5–9 μg/dL; and 60.4 ng/mL 
(95% CI: –90.9, –29.9) for BLLs ≥ 10 μg/dL.
conclusions: In peripubertal boys with low-level lead exposure, higher BLLs were associated with 
lower serum IGF-1. Inhibition of the hypothalamic–pituitary–growth axis may be one possible 
pathway by which lead exposure leads to growth delay.
key words: cohort studies, growth, insulin-like growth factor 1, lead; puberty.
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from the analysis because of implausibly low 
IGF-1 concentrations (< 50 ng/mL) despite 
normal height and body mass index (BMI) 
z-scores. Of the remaining 487 boys, 394 met 
inclusion criteria for this analysis, specifically, 
by availability of a baseline BLL (at 8–9 years) 
and follow-up serum IGF-1 concentration 
at both the 2-year (at 10–11 years) and the 
4-year (at 12–13 years) follow-up visits. None 
of the participants had IGF-1 measured at 
baseline or BLL measured at follow-up. The 
Russian Children’s Study was approved by 
the human studies institutional review boards 
(IRBs) of the Chapaevsk Medical Association, 
Harvard School of Public Health, Brigham 
and Women’s Hospital, and University of 
Massachusetts Medical School. The parent or 
guardian of each Russian Children’s Study par-
ticipant signed an informed consent form, and 
each boy signed an assent form. The present 
analysis was a secondary data analysis that was 
exempt from requirement for IRB review of 
already collected, deidentified data under fed-
eral and Children’s Hospital Boston policies.
Study assessment protocol. At study 
entry, boys underwent a physical examina-
tion and blood collection. We used a validated 
Russian Institute of Nutrition semiquanti-
tative food-frequency questionnaire to esti-
mate dietary intakes during the previous year 
(Martinchik et al. 1998; Rockett et al. 1997). 
Mothers or guardians also completed nurse-
administered health and lifestyle question-
naires that included information on birth, 
family and child medical histories, occupa-
tional and residential history, and measures 
of socioeconomic status (SES) such as house-
hold income and parental education. We 
obtained birth weight and gestational age from 
medical records.
Physical examination. A single study 
nurse who did not have knowledge of the 
boys’ BLLs performed standardized anthropo-
metric examinations, and a single investiga-
tor (O.S.) performed pubertal assessments at 
study entry and at annual follow-up visits. 
We measured height to the nearest 0.1 cm 
with a stadiometer. We measured weight 
to the nearest 100 g with a metric scale. 
We calculated age-adjusted percentiles for 
BMI (kilograms per meter squared) using 
the World Health Organization (WHO) 
standards (WHO 2011). For this analysis, 
pubertal status was based on testicular volume 
measured by Prader beads (orchidometer). 
Blood lead levels. Venous blood samples 
(3.0 mL) were collected in trace metal-free 
Vacutainer tubes (Becton-Dickinson, Franklin 
Lakes, NJ, USA), after cleansing the venipunc-
ture site with alcohol. Whole-blood samples 
were diluted with a matrix modifier solution 
and analyzed using Zeeman background cor-
rected, flameless graphite furnace, atomic 
absorption spectrometry (ESA Laboratories, 
Chelmsford, MA, USA). BLLs below the 
limit of detection (1 μg/dL) were imputed as 
0.5 μg/dL for 9 (2.2%) of 394 boys.
Serum IGF-1 concentrations. Serum 
IGF-1 concentrations were measured by 
a chemiluminescent immunometric assay 
using Siemens Immulite 2000 (Siemens 
AG, Munich, Germany). The assay is highly 
specific for IGF-1 with undetectable cross-
reactivity with insulin, pro-insulin, luteinizing 
hormone (LH), thyroid-stimulating hormone, 
or insulin-like growth factor-2. The detection 
limit was 20 ng/mL; no IGF-1 values were 
below the limit of detection. The intra-assay 
coefficient of variation (CV) was < 3.9%, 
and the inter-assay CV was < 8.1% for the 
Immulite 2000 kit.
Statistical analysis. We used repeated 
measures analysis to estimate the associa-
tion between BLL measured at 8–9 years of 
age and serum IGF-1 concentration at both 
the 2-year (at 10–11 years) and 4-year (at 
12–13 years) follow-up visits. The distribu-
tion of BLLs was right-skewed with out liers. 
We considered several different ways of evalu-
ating BLLs, including dichotomized as high 
(≥ 5 μg/dL) versus low (< 5 μg/dL) based on 
the new CDC threshold, as a continuous 
measure (log-transformed), and categorized as 
0–2, 3–4, 5–9, or ≥ 10 μg/dL. 
We fit linear regression models using a 
generalized estimating equation (GEE) 
approach to account for the repeated measures 
and slight skewness of IGF-1 concentrations. 
We first fit GEE linear regression models to 
evaluate unadjusted associations of high ver-
sus low BLL (≥ 5 or < 5 μg/dL) with serum 
IGF-1 concentrations. Next, we created a full 
multivariable model that included dichoto-
mized BLL, birth weight (continuous), gesta-
tional age at birth (continuous), breastfeeding 
duration (< 12, 12–24, or > 24 weeks), maxi-
mum parental education (secondary educa-
tion or less, junior college/technical training, 
or university graduate), monthly household 
income (< US$175, $175–250, or > $250), 
nutritional intake (total caloric intake and per-
cent calories from protein, fat, and carbohy-
drate as continuous variables), baseline and 
follow-up age (continuous), and baseline and 
follow-up BMI [underweight (BMI < 10th 
percentile), overweight (BMI > 85th percen-
tile), or normal weight]. We decided a priori 
not to consider height as a covariate due to its 
strong correlation with IGF-1 during puberty 
(Silbergeld et al. 1986). We then reduced this 
model by excluding covariates that did not 
predict the outcome with p ≤ 0.10, or did not 
change the estimated association between BLL 
and IGF-1 by > 10% when removed from the 
model, resulting in a final model that included 
baseline parental education, birth weight, 
nutritional intake, and baseline and follow-up 
age and BMI.
Because pubertal status is influenced by 
lead exposure (Selevan et al. 2003; Williams 
et al. 2010) and may be considered in the 
causal pathway between BLL and serum 
IGF-1 concentration, we fit the final reduced 
model both with and without adjustment 
for pubertal status [categorized based on tes-
ticular volume (TV) as prepubertal, ≤ 3 mL 
TV; early pubertal, > 3–6 mL TV; or mid-
pubertal, > 6–15 mL TV]. No boys in this 
analysis had a TV > 15 mL. We also evalu-
ated whether the association between BLL 
and IGF-1 concentration differed by puber-
tal stage by including an interaction term 
between pubertal status (prepubertal, early 
pubertal, or mid-pubertal) and BLL (≥ 5 or 
< 5 μg/dL).
Sensitivity analyses included the follow-
ing modifications to the final reduced model: 
a) inclusion of maternal and paternal heights 
as potential confounding variables for the 
subset of boys who had these values avail-
able (n = 337), b) inclusion of 44 additional 
boys with only one follow-up IGF-1 con-
centration, c) BLL categorized as ≤ 2, 3–4, 
5–9, or ≥ 10 μg/dL, and d) BLL modeled as a 
natural log-transformed continuous variable. 
We conducted all analyses using SAS version 
9.3 (SAS Institute Inc., Cary, NC, USA), 
and we considered two-sided p-values ≤ 0.05 
 statistically significant.
Results
Baseline growth and demographic character-
istics of the 394 boys included are shown in 
Table 1. The 95 eligible boys excluded from 
the present analysis were not significantly dif-
ferent from those included with regard to the 
characteristics shown in Table 1, except that 
they tended to have a higher percent protein 
intake at baseline and were more likely to have 
parents that had junior college or technical 
training (data not shown).
The median BLL at 8–9 years of age 
among boys included in the analysis was 
3 μg/dL (25th, 75th percentiles: 2 μg/dL, 
5 μg/dL; range, 0.5–31μg/dL). Most boys 
were prepubertal at baseline. The mean base-
line height z-score was slightly above the 
WHO average, and the mean baseline BMI 
z-score was slightly below the WHO average 
(Table 1).
In  unadjus ted  GEE model s  that 
accounted only for correlation among 
study visits, mean serum IGF-1 concentra-
tion during follow-up was 24.3 ng/mL 
lower (95% CI: –39.3, –9.3) among boys 
with BLL ≥ 5 μg/dL compared with those 
with < 5 μg/dL. A significantly lower mean 
IGF-1 concentration for boys with high ver-
sus low BLL was also estimated based on 
the full multivariable model (–28.0 ng/mL; 
95% CI: –43.1, –12.9) and the final reduced 
model (–29.2 ng/mL; 95% CI: –43.8, –14.5) 
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(Table 2). When pubertal status was added 
to the final reduced model, the association 
of high BLL with IGF-1 concentration was 
modestly attenuated (adjusted mean differ-
ence = –24.4 ng/mL; 95% CI: –37.7, –11.1).
The association of BLL with IGF-1 con-
centration differed according to pubertal sta-
tus. In particular, the reduction in adjusted 
mean IGF-1 concentrations between high 
versus low BLL groups was greater among 
boys in mid-puberty than for prepubertal 
boys (–41.9 ng/mL; 95% CI: –15.1, –68.7 
vs. –14.1 ng/mL; 95% CI: –0.9, –27.2; 
interaction p-value = 0.04). The reduction in 
adjusted mean IGF-1 concentrations between 
high versus low BLL groups was slightly larger 
for boys in early puberty (–18.0 ng/mL; 
95% CI: –3.5, –32.5) than for prepubertal 
boys (interaction p-value = 0.64) (Figure 1). 
Adjusted mean percent decreases in IGF-1 
concentrations between high versus low BLL 
groups were 9.3%, 12.2%, and 19.5% for 
prepubertal boys, boys in early puberty, and 
boys in mid-puberty, respectively.
In sensitivity analyses, further adjustment 
for parental heights among the subset of boys 
(n = 337) with these measures available had 
no appreciable impact on the estimated dif-
ference in IGF-1 concentrations for boys with 
high versus low BLL (adjusted mean differ-
ence = –31.6 ng/mL; 95% CI: –48.2, –15.0). 
The estimated difference in IGF-1 was also 
similar based on a model that included 
follow-up IGF-1 concentrations for 438 
boys with at least one IGF-1 measurement 
(adjusted mean difference = –28.8 ng/mL; 
95% CI: –42.5, –15.1).
When BLL was divided into finer cate-
gories, adjusted mean IGF-1 concentra-
tions decreased monotonically relative to 
Table 1. Baseline and follow-up characteristics of 394 boys from Chapaevsk, Russia, with baseline blood 
lead levels and two longitudinal measures of serum IGF-1.
Variable 8–9 years old (baseline) 10–11 years old 12–13 years old
Age (years) [median (range)] 8.1 (7.8–9.4) 10.1 (9.9–11.5) 12.1 (11.9–13.5)
BMI (WHO z-score)
Mean ± SD –0.2 ± 1.3 –0.2 ± 1.3 –0.2 ± 1.4
≤ 10th percentile [n (%)] 67 (17) 83 (21) 75 (19)
> 85th percentile [n (%)] 58 (15) 83 (21) 70 (18)
Height (WHO z-score) (mean ± SD) 0.14 ± 1.0 0.14 ± 1.0 0.03 ± 1.1
Testicular volume (mL) [n (%)]
≤ 3 (prepubertal) 336 (86)a 213 (54) 52 (13)a
> 3–6 55 (14) 153 (39) 104 (27)
> 6 0 (0) 28 (7) 235 (60)
IGF-1 (ng/mL) (mean ± SD) 146.9 ± 52.1 253.5 ± 115.9
Birth weight (kg) (mean ± SD)b 3.34 ± 0.52
Gestational age (weeks) (mean ± SD)a 39.01 ± 1.74
Breastfeeding duration (weeks) [median (IQR)]c 13.0 (30.3)
Baseline nutritional intake (mean ± SD)d
Total kcal/day 2,837 ± 972
Percent fat 34.1 ± 5.8
Percent protein 11.5 ± 1.6
Percent carbohydrate 54.4 ± 6.5
Monthly household income (US$) [n (%)]d
< 175 136 (35)
175–250 107 (27)
> 250 150 (38)
Maximal parental education [n (%)]a
Secondary education or less 25 (6)
Junior college/technical training 244 (62)
University graduate 122 (31)
Blood lead level (μg/dL)
Median (IQR) 3.0 (3.0)
< 5 [n (%)] 285 (72)
≥ 5 [n (%)] 109 (28)
IQR, interquartile range. 
aFive subjects missing. bTwo subjects missing. cFive subjects missing. dOne subject missing. 
Table 2. Repeated measures generalized estimating equation models predicting the mean levels of serum 
concentrations of IGF-1 (ng/mL) in relation to blood lead levels and relevant covariates.
Covariate
Full multivariable model 
(n = 385 boys, 767 visits)
Final reduced model 
(n = 389 boys, 775 visits)
Adjusted mean  
change (95% CI) p-Value
Adjusted mean 
change (95% CI) p-Value
Lead (μg/dL)
< 5 Reference Reference
≥ 5 –28.0 (–43.1, –12.9) < 0.001 –29.2 (–43.8, –14.5) < 0.001
Age (years) 51.9 (47.2, 56.6) < 0.001 52.1 (42.4, 56.8) < 0.001
Birth weight (kg) –17.4 (–33.2, –1.5) 0.03 –17.5 (–31.5, –3.5) 0.01
BMI z-score (percentile)
≤ 10 –58.6 (–73.9, –43.3) < 0.001 –61.3 (–76.7, –45.8) < 0.001
> 10–85 Reference Reference
> 85 13.8 (–4.4, 31.9) 0.14 12.9 (–5.2, 30.9) 0.16
Nutritional intake
Total caloriesa –2.6 (–10.7, 5.6) 0.54 –2.6 (–10.6, 5.5) 0.54
Fat (percent) 1.4 (0.2, 2.6) 0.02 1.3 (0.1–2.5) 0.03
Protein (percent) 3.0 (–1.6, 7.6) 0.21 3.1 (–1.4, 7.6) 0.18
Parental education
Secondary education or less –22.5 (–45.8, 0.8) 0.06 –24.9 (–47.7, –2.0) 0.03
Junior college/technical training –3.4 (–19.3, 12.5) 0.69 –2.7 (–18.4, 13.0) 0.74
University graduate Reference Reference
Monthly household income (US$)
< 175 –3.3 (–20.3, 13.8) 0.71
175–250 –6.4 (–23.7, 10.9) 0.47
> 250 Reference
Gestational age (weeks) 0.4 (–4.2, 5.1) 0.85
Breastfeeding (weeks)
< 12 Reference
12–24 0.7 (–18.2, 19.7) 0.94
> 24 1.1 (–14.1, 16.4) 0.88
aPer 1,000 calories.
Figure  1. Adjusted mean IGF-1 concentrations 
for high versus low BLL by pubertal status. The 
adjusted mean IGF-1 difference for high versus low 
BLL was 14 ng/mL in prepubertal boys, 18 ng/mL 
in early-pubertal boys, and 42  ng/mL in mid- 
pubertal boys. Compared with prepubertal boys, 
the lead-associated IGF-1 difference was larger in 
mid-pubertal boys (p = 0.04) and larger, but not sig-
nificantly larger, in early-pubertal boys (p = 0.65).
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the reference group: –12.8 ng/mL (95% CI: 
–29.9, 4.4; n = 176) for BLL = 3–4 μg/dL; 
–34.5 ng/mL (95% CI: –53.1, –16.0; n = 97) 
for BLL 5–9 μg/dL; and –60.4 ng/mL 
(95% CI: –90.9, –29.9; n  = 12) for 
BLL ≥ 10 μg/dL, compared with BLL 
≤ 2 μg/dL (n = 109) (Figure 2). Finally, each 
unit increase in natural log-transformed BLL 
was associated with a 22.2-ng/mL decrease in 
mean serum IGF-1 (95% CI: –33.9, –10.6).
Discussion
We observed a negative association between 
BLLs measured at 8–9 years of age and 
serum IGF-1 concentrations at 10–11 and 
12–13 years of age that was stronger among 
boys in mid-puberty than in prepubertal 
boys. This finding suggests one possible expla-
nation for our previous finding of lower mean 
height z-scores for boys in the same cohort 
with BLL ≥ 5 μg/dL compared with BLL 
< 5 μg/dL (Burns et al. 2012). Results from 
the present analysis suggest a montonic dose–
response relationship between BLL and serum 
IGF-1 that adds further support to existing 
evidence of physiological effects of BLLs 
< 10 μg/dL (Ballew et al. 1999; Bellinger 
et al. 1992; Gump et al. 2005; Kafourou et al. 
1997; Karmaus et al. 2005; Lanphear et al. 
2005; Little et al. 2009; Menke et al. 2006; 
Naicker et al. 2010; Selevan et al. 2003; 
Shukla et al. 1991; Williams et al. 2010).
A negative association between BLL and 
serum IGF-1 concentrations is consistent with 
lead-induced inhibition of the hypothalamic–
pituitary–growth axis. An in vitro study in rat 
pituitary demonstrated that lead blocked the 
binding of growth hormone releasing hor-
mone to its receptor, suggesting axis inhibition 
at the level of the pituitary (Lau et al. 1991). 
Lead could also affect the growth axis at the 
level of the pituitary through interference with 
calcium-dependent GH release. In in vitro 
studies of bovine and rat pituitary, other 
 divalent cations such as zinc, nickel, cadmium, 
and magnesium blocked calcium-dependent 
GH release (Carlson 1984; Lorenson et al. 
1983), although additional studies are needed 
to determine whether this effect persists in 
in vivo and whether lead elicits similar actions. 
Consistent with these potential pituitary-
mediated effects, a study of rodent pups (mean 
BLL, 18 μg/dL) demonstrated suppressed 
growth hormone releasing hormone-stimu-
lated GH release (Camoratto et al. 1993), and 
in a separate rodent model, high lead expo-
sure (up to mean BLL of 263 μg/dL) resulted 
in lower serum IGF-1 concentrations (Ronis 
et al. 1998a). Highly lead-exposed prepubertal 
children (n = 6) had decreased mean 24-hr 
serum GH concentrations and lower serum 
IGF-1 concentrations before chelation (BLLs 
> 40 μg/dL) compared with after chelation 
(BLLs ≤ 30 μg/dL) (Huseman et al. 1992). 
In contrast to these studies, the present analy-
sis explored BLLs within currently acceptable 
ranges and still found a negative association 
between BLL and IGF-1.
Lead may also inhibit the reproductive 
axis at the level of the pituitary. Six men 
with occupational lead exposure (mean BLL, 
38.7 μg/dL) had blunted LH response to 
gonadotropin-releasing hormone (GnRH) 
compared with nine men without occupa-
tional exposure (mean BLL, 16 μg/dL) 
(Braunstein et al. 1978). In a study of 77 lead 
smelter workers (mean BLL, 33 μg/dL) and 
26 nonworkers (mean BLL, 4.1 μg/dL), a 
subset analysis demonstrated lower GnRH-
stimulated follicle-stimulating hormone in 9 
workers compared to 11 nonworkers (Erfurth 
et al. 2001). Also, lead exposure in rodents 
resulted in decreased serum LH concentra-
tion (Ronis et al. 1998b) and increased pitui-
tary LH stores (Klein et al. 1994; Sokol et al. 
1998), further suggesting possible pituitary 
hyporesponsiveness to GnRH. Consistent 
with these studies of gonadotropin inhibi-
tion, lead exposure has been associated with 
later onset of puberty in our cohort (Williams 
et al. 2010) and in other adolescent cohorts 
(Naicker et al. 2010; Selevan et al. 2003).
A lead-induced decrement in IGF-1 may 
contribute to gonadotropin inhibition and 
pubertal delay. Specifically, IGF-1 has been 
shown to activate GnRH in vitro (Zhen 
et al. 1997) and in rodent models (Hiney 
et al. 1991, 1996), and puberty is delayed 
in GnRH-specific IGF-1 receptor knock-
out mice (Divall et al. 2010). Furthermore, 
IGF-1 administration to lead-exposed mice 
with delayed puberty restored pubertal timing 
(Pine et al. 2006), providing additional evi-
dence for a potential mediating role of IGF-1 
in the association between lead exposure and 
delayed puberty.
In addition to inhibition of GH and 
gonadotropin release, in animal studies, high 
lead exposure has been associated with other 
processes that could lead to growth delay such 
as decreased food consumption (Hammond 
et al. 1989, 1990) and reduced formation 
of new bone (Hass et al. 1967; Hicks et al. 
1996). Future studies should explore whether 
these effects can be observed in humans with 
low-level lead exposures.
As far as we are aware, our study is the 
first to identify puberty as a particularly vul-
nerable period in which to assess lead’s effect 
on IGF-1. Both the absolute and percent 
decrease in IGF-1 in association with lead 
exposure was larger in mid-pubertal boys than 
in prepubertal or early-pubertal boys. Thus, in 
our cohort, puberty seemed to be a key time 
period in which to detect an effect of lead, 
and this may be generalizable to other envi-
ronmental epidemiologic studies examining 
outcomes of growth and associated hormones.
The present study is limited by avail-
ability of the BLL measurement at only one 
time point, leading to an inability to explore 
other vulnerable windows of exposure, such 
as exposures during infancy that may have a 
stronger association with childhood height 
(Afeiche et al. 2012). Also, none of the par-
ticipants had a baseline IGF-1 measurement. 
However, we believe that a prospective evalu-
ation of BLL on subsequent IGF-1 values 
made for a stronger study design.
Future studies of lead and growth would 
benefit from measurement of serum insulin-
like growth factor-binding protein 3, a less 
nutritionally dependent measure of GH activ-
ity. Inclusion of girls in future studies will also 
be important, because rodent models suggest 
that lead’s effect on pubertal growth may be 
more pronounced in males than in females 
(Ronis et al. 1998a). Furthermore, the net 
effect of lead on growth in humans cannot 
be completely understood without informa-
tion on the association between childhood 
lead exposures and adult height, so continued 
longitudinal follow-up through adulthood is 
warranted for this and other cohorts.
Conclusion
In the present study we found a negative 
monotonic dose–response association between 
blood lead levels in boys at 8–9 years of age 
and their serum IGF-1 concentrations at 
10–11 and 12–13 years of age. With increas-
ing attention to environmental exposures and 
potential health risks, it is essential to better 
understand effects of low-level lead expo-
sure on key developmental processes such as 
growth and reproductive development.
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